Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.